Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Performance Enhancing Drugs Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 Ergogenic Aids
  • 1.3.3 Nootropic
• 1.4 Market Segment by Application
  • 1.4.1 Global Performance Enhancing Drugs Market Share by Application (2019-2025)
  • 1.4.2 Athletes
  • 1.4.3 Body Builders
  • 1.4.4 Students
  • 1.4.5 Militaries
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Performance Enhancing Drugs Market Size
  • 2.1.1 Global Performance Enhancing Drugs Revenue 2014-2025
  • 2.1.2 Global Performance Enhancing Drugs Sales 2014-2025
• 2.2 Performance Enhancing Drugs Growth Rate by Regions
  • 2.2.1 Global Performance Enhancing Drugs Sales by Regions 2014-2019
  • 2.2.2 Global Performance Enhancing Drugs Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Performance Enhancing Drugs Sales by Manufacturers
  • 3.1.1 Performance Enhancing Drugs Sales by Manufacturers 2014-2019
  • 3.1.2 Performance Enhancing Drugs Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 Performance Enhancing Drugs Revenue by Manufacturers (2014-2019)
  • 3.2.2 Performance Enhancing Drugs Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Performance Enhancing Drugs Market Concentration Ratio (CR5 and HHI)
• 3.3 Performance Enhancing Drugs Price by Manufacturers
• 3.4 Key Manufacturers Performance Enhancing Drugs Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Performance Enhancing Drugs Market
• 3.6 Key Manufacturers Performance Enhancing Drugs Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 Ergogenic Aids Sales and Revenue (2014-2019)
  • 4.1.2 Nootropic Sales and Revenue (2014-2019)
• 4.2 Global Performance Enhancing Drugs Sales Market Share by Type
• 4.3 Global Performance Enhancing Drugs Revenue Market Share by Type
• 4.4 Performance Enhancing Drugs Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Performance Enhancing Drugs Sales by Application

6 United States

• 6.1 United States Performance Enhancing Drugs Breakdown Data by Company
• 6.2 United States Performance Enhancing Drugs Breakdown Data by Type
• 6.3 United States Performance Enhancing Drugs Breakdown Data by Application

7 European Union

• 7.1 European Union Performance Enhancing Drugs Breakdown Data by Company
• 7.2 European Union Performance Enhancing Drugs Breakdown Data by Type
• 7.3 European Union Performance Enhancing Drugs Breakdown Data by Application

8 China

• 8.1 China Performance Enhancing Drugs Breakdown Data by Company
• 8.2 China Performance Enhancing Drugs Breakdown Data by Type
• 8.3 China Performance Enhancing Drugs Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World Performance Enhancing Drugs Breakdown Data by Company
• 9.2 Rest of World Performance Enhancing Drugs Breakdown Data by Type
• 9.3 Rest of World Performance Enhancing Drugs Breakdown Data by Application
• 9.4 Rest of World Performance Enhancing Drugs Breakdown Data by Countries
  • 9.4.1 Rest of World Performance Enhancing Drugs Sales by Countries
  • 9.4.2 Rest of World Performance Enhancing Drugs Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 Taj Pharmaceuticals
  • 10.1.1 Taj Pharmaceuticals Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of Performance Enhancing Drugs
  • 10.1.4 Performance Enhancing Drugs Product Introduction
  • 10.1.5 Taj Pharmaceuticals Recent Development
• 10.2 Balkan Pharmaceuticals
  • 10.2.1 Balkan Pharmaceuticals Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of Performance Enhancing Drugs
  • 10.2.4 Performance Enhancing Drugs Product Introduction
  • 10.2.5 Balkan Pharmaceuticals Recent Development
• 10.3 Bayer
  • 10.3.1 Bayer Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of Performance Enhancing Drugs
  • 10.3.4 Performance Enhancing Drugs Product Introduction
  • 10.3.5 Bayer Recent Development
• 10.4 AstraZeneca
  • 10.4.1 AstraZeneca Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of Performance Enhancing Drugs
  • 10.4.4 Performance Enhancing Drugs Product Introduction
  • 10.4.5 AstraZeneca Recent Development
• 10.5 Novo Nordisk
  • 10.5.1 Novo Nordisk Company Details
  • 10.5.2 Company Description and Business Overview
  • 10.5.3 Sales, Revenue and Market Share of Performance Enhancing Drugs
  • 10.5.4 Performance Enhancing Drugs Product Introduction
  • 10.5.5 Novo Nordisk Recent Development
• 10.6 BrainAlert
  • 10.6.1 BrainAlert Company Details
  • 10.6.2 Company Description and Business Overview
  • 10.6.3 Sales, Revenue and Market Share of Performance Enhancing Drugs
  • 10.6.4 Performance Enhancing Drugs Product Introduction
  • 10.6.5 BrainAlert Recent Development
• 10.7 Douglas Laboratories
  • 10.7.1 Douglas Laboratories Company Details
  • 10.7.2 Company Description and Business Overview
  • 10.7.3 Sales, Revenue and Market Share of Performance Enhancing Drugs
  • 10.7.4 Performance Enhancing Drugs Product Introduction
  • 10.7.5 Douglas Laboratories Recent Development
• 10.8 Onnit Labs
  • 10.8.1 Onnit Labs Company Details
  • 10.8.2 Company Description and Business Overview
  • 10.8.3 Sales, Revenue and Market Share of Performance Enhancing Drugs
  • 10.8.4 Performance Enhancing Drugs Product Introduction
  • 10.8.5 Onnit Labs Recent Development
• 10.9 Eli Lilly And Company
  • 10.9.1 Eli Lilly And Company Company Details
  • 10.9.2 Company Description and Business Overview
  • 10.9.3 Sales, Revenue and Market Share of Performance Enhancing Drugs
  • 10.9.4 Performance Enhancing Drugs Product Introduction
  • 10.9.5 Eli Lilly And Company Recent Development

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 Performance Enhancing Drugs Sales Channels
  • 11.2.2 Performance Enhancing Drugs Distributors
• 11.3 Performance Enhancing Drugs Customers

12 Market Forecast

• 12.1 Global Performance Enhancing Drugs Sales and Revenue Forecast 2019-2025
• 12.2 Global Performance Enhancing Drugs Sales Forecast by Type
• 12.3 Global Performance Enhancing Drugs Sales Forecast by Application
• 12.4 Performance Enhancing Drugs Forecast by Regions
  • 12.4.1 Global Performance Enhancing Drugs Sales Forecast by Regions 2019-2025
  • 12.4.2 Global Performance Enhancing Drugs Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details

Performance-enhancing drugs (PED), are substances that are used to improve any form of activity performance in humans.
A well-known example of PED involves doping in sport, where banned physical performance–enhancing drugs are used by athletes and bodybuilders. Athletic performance-enhancing substances are sometimes referred to as ergogenic aids. Cognitive performance-enhancing drugs, commonly called nootropics, are sometimes used by students to improve academic performance. Performance-enhancing substances are also used by military personnel to enhance combat performance.
In 2019, the market size of Performance Enhancing Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Performance Enhancing Drugs.

This report studies the global market size of Performance Enhancing Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Performance Enhancing Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Taj Pharmaceuticals
Balkan Pharmaceuticals
Bayer
AstraZeneca
Novo Nordisk
BrainAlert
Douglas Laboratories
Onnit Labs
Eli Lilly And Company

Market Segment by Product Type
Ergogenic Aids
Nootropic

Market Segment by Application
Athletes
Body Builders
Students
Militaries

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Performance Enhancing Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Performance Enhancing Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Performance Enhancing Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025